Company: SCLXW
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0000950170-25-007391
Chunk: 8

Company: Scilex Holding Co
Filing Date: 2025-01-21
Form: 424B3
Chunk 8
---
ilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.

Gloperba® is the subject of an exclusive, transferable license to Scilex Holding Company to use the registered trademark.

ELYXYB® is a registered trademark owned by Scilex Holding Company.

Page |6

All other trademarks are the property of their respective owners.

© 2025 Scilex Holding Company All Rights Reserved.

Page |7

Exhibit 99.2

FOR IMMEDIATE RELEASE

January 21, 2025

Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)

PALO ALTO, CALIFORNIA – January 21, 2025 (GLOBE NEWSWIRE) -Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, neurodegenerative and cardiometabolic disease, today announced that it has received notification from The Nasdaq Stock Market LLC that the Company has regained compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024.

For more information on Scilex Holding Company, refer towww.scilexholding.com

For more information on Semnur Pharmaceuticals, Inc., refer towww.semnurpharma.com

For more information on Scilex Holding Company Sustainability Report, refer towww.scilexholding.com/investors/sustainability

For more information on ZTlido® including Full Prescribing Information, refer towww.ztlido.com.

For more information on ELYXYB®, including Full Prescribing Information, refer towww.elyxyb.com.

For more information on Gloperba®, including Full Prescribing Information, refer towww.gloperba.com.

About Scilex Holding Company

Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large